Igor Vivanco, PhD, King’s College London, UK, discusses the current challenges facing clinical trials involving patients with primary brain tumors. Dr Vivanco explains that permission for clinical trials investigating possible targets in glioblastoma patients is often not granted, resulting in few glioblastoma trials being conducted. One reason for this is that diseases relating to the brain are often viewed as an exclusion criterion, discouraging the inclusion of these patients in trials. Dr Vivanco then goes on to explain the need for better pre-clinical models to increase understanding of how drugs interact with tumors. This interview took place at the ESMO Targeted Anticancer therapies (TAT) Congress 2021 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
